Company Overview
Company Type: Private Company
Website: aspectbiosystems.com
Number of Employees: -
Year Founded: 2013
Total Amount Raised (CAD mm)†: 27.20
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Aspect Biosystems Ltd. operates as a biotechnology company that engages in 3D bioprinting and tissue engineering. The company offers engineering physiologically relevant 3D living tissues through its 3D bioprinting platform technology. It provides Lab-on-a-printer technology that enables control over biomaterial composition and structure during tissue fabrication. It offers contract testing services on the human tissue model. Its customers include pharmaceutical firms and academics engaged in defining pathways in respiratory diseases. The company has a partnership with JDRF International. The company was founded in 2013 and is based in Vancouver, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Mohamed, Tamer 
Co-Founder, President, CEO & Director
Beyer, Simon 
Co-Founder & Chief Technology Officer
Wadsworth, Sam 
Co-Founder and Chief Scientific Officer
Smith, Ray 
Chief Financial Officer
Korenic, Natalie 
Head of Marketing & Communications
Gardiner, Diane Kathleen
Chief Human Resources Officer
Bedford, Erin 
Head of Bioprinting Innovation
Harvey, Jack 
Senior Vice President of Process Development & Manufacturing
Mackenzie, Lloyd F.
Chief Technical Operations Officer
Roos, Eric 
Chief Business Development Officer
Chen, Sissi 
Financial Controller

Key Board Members
Name
Title
Mohamed, Tamer 
Co-Founder, President, CEO & Director
Bissonnette, Christopher 
Director
Haughian, Andrew
Director
Haut, Donald D.
Director
Krieger, Nancy 
Director
Smith, Devyn M.
Director
Teja, Salim 
Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
1781 West 75th Avenue | Vancouver, BC | V6P 6P2 | Canada
Phone: 604 263 0502   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
Radical Ventures Investments Inc.
Jan-09-2020
Minority
-
Series A
Daniel Mulet, Salim Teja
Rhino Ventures
Jan-09-2020
Unknown
-
Series A
Jay Rhind
Genome British Columbia
May-07-2018
Minority
-
Venture
-
Endure Capital
Sep-18-2017
Minority
-
Venture
-
Pallasite Ventures
Sep-18-2017
Unknown
-
Venture
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-09-2020
Jan-09-2020
Private Placement
Target
Aspect Biosystems Ltd.
Pangaea Ventures Ltd.,Pallasite Ventures,Radical Ventures Investments Inc.,Rhino Ventures

20.00
May-07-2018
May-07-2018
Private Placement
Target
Aspect Biosystems Ltd.
Genome British Columbia

0.78
Sep-18-2017
Sep-18-2017
Private Placement
Target
Aspect Biosystems Ltd.
Endure Capital,Pangaea Ventures Ltd.,Pallasite Ventures,Relentless Pursuits Partners, Inc.

-
Jul-30-2015
Jul-30-2015
Private Placement
Target
Aspect Biosystems Ltd.


-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-21-2023
Executive/Board Changes - Other
Aspect Biosystems Announces Appointment of Lloyd Mackenzie as Chief Technical Operations Officer
Aug-16-2023
Executive/Board Changes - Other
Aspect Biosystems Appoints Diane Gardiner as Chief Human Resources Officer
Apr-12-2023
Company Conference Presentations
Aspect Biosystems Ltd. Presents at The Cell & Gene Meeting on the Mediterranean, Apr-12-2023 12:00 PM
Apr-12-2023
Client Announcements
Aspect Biosystems and Novo Nordisk A/S Enter Partnership to Develop Bioprinted Tissue Therapeutics for Diabetes and Obesity
Oct-11-2022
Company Conference Presentations
Aspect Biosystems Ltd. Presents at The Cell & Gene Meeting on the Mesa 2022, Oct-11-2022 10:45 AM


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 07:05 PM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd
Reports
65
GlobalData

Aug 23, 2023 06:35 AM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd - Medical Equipment - Deals and Alliances Profile
Reports
23
GlobalData

Jul 14, 2023 05:40 AM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd - Medical Devices Product Pipeline Summary
Reports
24
GlobalData

Jun 19, 2023 05:34 AM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd
Reports
51
GlobalData

Jun 09, 2023 07:53 AM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd - Medical Devices Product Pipeline Summary
Reports
24
GlobalData

May 09, 2023 03:57 AM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd - Medical Equipment - Deals and Alliances Profile
Reports
23
GlobalData

Mar 15, 2023 12:23 AM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd
Reports
49
GlobalData

Mar 10, 2023 02:30 AM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd - Medical Devices Product Pipeline Summary
Reports
24
GlobalData

Jan 23, 2023 04:58 AM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd - Medical Equipment - Deals and Alliances Profile
Reports
23
GlobalData

Dec 14, 2022 11:17 PM
Aspect Biosystems Ltd.
Aspect Biosystems Ltd
Reports
49


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Upcoming Events
Date/Time
Type
Oct-10-2023
Conferences
Oct-10-2023 3:00 PM (PST)
Company Conference Presentations
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Mohamed, Tamer 
Co-Founder, President, CEO & Director
604 263 0502
-

Bissonnette, Christopher 
Director
604 263 0502
-

Haughian, Andrew
Director
604 263 0502
-
andrew@pangaeaventures.com
Haut, Donald D.
Director
604 263 0502
-

Krieger, Nancy 
Director
604 263 0502
-

Smith, Devyn M.
Director
604 263 0502
-

Teja, Salim 
Director
604 263 0502
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Mohamed, Tamer 
Co-Founder, President, CEO & Director
604 263 0502
-

Beyer, Simon 
Co-Founder & Chief Technology Officer
604 263 0502
-

Wadsworth, Sam 
Co-Founder and Chief Scientific Officer
604 263 0502
-

Smith, Ray 
Chief Financial Officer
604 263 0502
-

Korenic, Natalie 
Head of Marketing & Communications
604 263 0502
-

Gardiner, Diane Kathleen
Chief Human Resources Officer
604 263 0502
-

Bedford, Erin 
Head of Bioprinting Innovation
604 263 0502
-

Harvey, Jack 
Senior Vice President of Process Development & Manufacturing
604 263 0502
-

Mackenzie, Lloyd F.
Chief Technical Operations Officer
604 263 0502
-

Roos, Eric 
Chief Business Development Officer
604 263 0502
-

Chen, Sissi 
Financial Controller
604 263 0502
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
